BioCentury | Dec 3, 2020
Deals

Artios picks Germany’s Merck for first major pharma collaboration in synthetic lethality

...damage repair, with programs in Phase I and Phase II testing. Merck obtained molecules targeting ATR...
...new ways of inducing synthetic lethality has raised interest in other targets, such as the ATR...
...does not include the biotech’s two most advanced programs, which target ATR and POLQ. The ATR...
BioCentury | Nov 21, 2020
Finance

Mei readies Antengene to take its next steps to becoming a global biotech

...synthetic lethality program ATG-018, which is an ATR...
...Tumor necrosis factor receptor superfamily member 9ATR (FRP1...
BioCentury | Jul 22, 2020
Management Tracks

Meeker expands role at Rhythm; plus Biogen, Kronos, Citryll, Akcea, ImmunoGen, Circle, Antares and more

David Meeker will become president and CEO of obesity company Rhythm Pharmaceuticals Inc. (NASDAQ:RYTM) while remaining chairman, a title he’s held since 2017. He succeeds CFO Hunter Smith, who was serving as president and CEO...
BioCentury | Jun 20, 2020
Finance

Forma, Repare shine in first-day performances as biotech IPOs on NASDAQ maintain momentum

...Sandler. Repare plans to start a Phase I/II trial next quarter of its lead program, ATR...
...Targets ATM - Ataxia telangiectasia mutated ATR (FRP1) - Ataxia telangiectasia and Rad3 related (ATR...
BioCentury | May 30, 2020
Translation in Brief

Empirica’s glioblastoma CAR T therapy in mice; plus tumor microbiomes by tumor type, Senhwa and more

...Senhwa synthetic lethal compound CX-5461 from Senhwa Biosciences Inc. (TPEx:6492) activates the replication stress sensor ATR...
...CX-5461 exhibits synthetic lethality with PARP inhibition in high-grade serous ovarian cancer (HGSOC) cells. The ATR...
...PCBP1 activity could serve as a predictor of patient response to checkpoint inhibitors. Targets ATR (FRP1...
BioCentury | May 28, 2020
Deals

In its first broad deal, Repare leads BMS deeper into synthetic lethality

...such as BRCA1, has launched a search for similarly potent inhibitor-mutation pairings (see “Following PARP, ATR...
...Phase I testing for multiple solid cancers. Repare plans to test its lead program, preclinical ATR...
...develop and commercialize Repare’s POLQ inhibitor in Japan and other select Asian territories. Targets ATR (FRP1...
BioCentury | Apr 25, 2020
Targets & Mechanisms

Trends to surf for at AACR 2020

...already gained traction, such as PARP and ATR ( No. 1058 ) (see “Following PARP, ATR...
...on a radioligand therapy ( No. CT159 ) (see “Radiotherapy Blasts Forward” ). Targets ATR (FRP1...
BioCentury | Jan 17, 2020
Translation in Brief

CPSF3 emerges as new synthetic lethality target in AML and sarcoma

...that interact with PARP inhibition and novel DNA damage repair targets, including members of the ATR...
...outside of DNA damage repair pathways (see “Broadening the PARP Playing Field” ; “Following PARP, ATR...
...of the mRNA processing complex for identifying novel therapeutic targets for lineage-selective killing. Targets ATR (FRP1...
BioCentury | Oct 16, 2019
Financial News

Oct. 15 Financial Quick Takes: Phathom, Galera, J&J earnings, RTW Investments, Azitra, MaveriX

...$17 million. Connecticut Innovations and Godfrey Capital participated in the round. The company’s lead program, ATR-04...
...MaveriX is eligible to receive up to $138 million in milestone payments from Sotio. BioCentury Staff Azitra Inc. ATR-04 MVX-5005 MaveriX...
BioCentury | Sep 4, 2019
Finance

Repare readies for clinic with Cowen-led $82M B round

...the bulk of the funds will go towards clinical and preclinical testing, Segal said. Repare’s ATR...
...behind that. The funds will take Repare through the initial clinical data readouts on its ATR...
...joined Repare’s board, as did OrbiMed’s David Bonita. Targets: ATM - Ataxia telangiectasia mutated; ATR (FRP1...
Items per page:
1 - 10 of 116